Preview

Pharmacokinetics and Pharmacodynamics

Advanced search

Evaluation of immunotoxicity of the extended-release form of Afobazol

https://doi.org/10.37489/2587-7836-2020-3-48-51

Abstract

The research of immunotoxicity of extended-release form of Afobazol was conducted on male CBA, C57BL/6 and F1 hybrids (CBA×C57BL/6) mice. Afobazol was administered per os for 14 days in doses of 12 mg/kg and 120 mg/kg. Control group received a placebo. Weight of thymus, spleen and popliteal lymph nodes was not affected by the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg in F1 hybrids (CBA×C57BL/6) mice compared to the control group (p> 0.05). Cellularity of thymus was significantly increased by the extended-release form of Afobazol in dose of 12 mg/kg (p< 0.01 vs control group). Administration of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg decreased spontaneous chemiluminescence activity of peripheral blood lymphocytes in 2.0 and 2.2 times, in dose of 120 mg/kg level integral chemiluminescence response S was decreased in 2.4 times (p< 0.05 vs control group). Phagocytic activity of peritoneal macrophages and antibody production in F1 hybrids (CBA×C57BL/6) mice were not affected by administration of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg (p > 0.05 vs control group). 14 days of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg did not cause any significant change to intensity of delayed-type hypersensitivity reactions (p> 0.05 vs control group). The results of the study allow us to conclude that administration of the extended-release form Afobazol in the range of studied doses does not induce immunotoxicity.

About the Authors

L. P. Kovalenko
FSBI «Zakusov Institute of Pharmacology»
Russian Federation

Kovalenko Larisa P., D. Sci. in Biology, Leading Researcher of drug 
toxicology department

SPIN code: 5185-4250



R. V. Zhurikov
FSBI «Zakusov Institute of Pharmacology»
Russian Federation

Zhurikov Ruslan V. , Junior researcher of laboratory of drug toxicology

SPIN code: 6648-1794



K. V. Korzhova
FSBI «Zakusov Institute of Pharmacology»
Russian Federation

Korzhova Ksenia V., Junior researcher of laboratory of drug toxicology

SPIN code: 3831-3782



A. D. Durnev
FSBI «Zakusov Institute of Pharmacology»
Russian Federation

Durnev Andrei D., D. Sci. in Medicine, professor, RAS corresponding member of the RAS, Head of the department of drug toxicology, Director

SPIN code: 8426-0380



References

1. Seredenin SB, Voronin MV. Neuroreceptor mechanisms involved in the action of afobazole. Eksperimental'naia i klinicheskaia farmakologiia. 2009;72(1):3–11. (In Russ).]. DOI: 10.30906/0869-2092-2009-72-1-3-11.

2. Kadnikov IA, Voronin MV, Seredenin SB. Effect of afobazole on the activity of quinone reductase 2. Khimiko-farmatsevticheskii zhurnal.2013:47(10);9–11. (In Russ).]. DOI: 10.30906/0023-1134-2013-47-10-9-11.

3. Haitov RM, Ivanova AS, Kovalenko LP, et al. Metodicheskie rekomendacii po ocenke immunotoksicheskogo dejstviya farmakologicheskih veshchestv. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Part one. /Ed by AN Mironova. Moscow: Grif i K; 2012. p. 64–79. (In Russ).].

4. Haitov RM, Gushchin IS, Pinegin BV, et al. Metodicheskie rekomendacii po doklinicheskomu izucheniyu immunotropnoj aktivnosti farmakologicheskih veshchestv. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Part one. / Ed by AN Mironova. Moscow: Grif i K; 2012. p. 626–656. (In Russ).].


Review

For citations:


Kovalenko L.P., Zhurikov R.V., Korzhova K.V., Durnev A.D. Evaluation of immunotoxicity of the extended-release form of Afobazol. Pharmacokinetics and Pharmacodynamics. 2020;(3):48-51. (In Russ.) https://doi.org/10.37489/2587-7836-2020-3-48-51

Views: 400


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2587-7836 (Print)
ISSN 2686-8830 (Online)